Internet leader at a bargain price

(Full access for Members only)

Internet leader at a bargain price

15 August 2024

The company featured in this report has pulled off what most other Internet companies can only dream of:

  • Its name has literally defined its own category.
  • Over 80% of its web traffic is organic or direct.
  • Its revenue per employee is nearly 3x that of its peer average.

However, it has hit a weak patch lately:

  • After growing 100% in two years, its recent growth has been 0%.
  • Corporate behemoths from around the world have tried to take market share.
  • Management had gotten a bit carried away with expensive acquisitions, and these had to be wound down.

As a result, its stock is currently down 85%.

Still, there is a lot of inherent strength to the company:

  • Highly cash-generative, with 90% of its EBITDA converting to free cash flow.
  • Tremendous loyalty among its most important user group.
  • The brand remains category-defining.

Right now, the market has lost interest, and barely anyone even pays attention – except one particular investor who has a golden track record in contrarian technology investing. The investor in question recently mopped up shares to become the single-largest shareholder – and bought even more in the days before this report came out!

If you missed buying Meta or Spotify in 2022, this is a similar case to look at.

Not a Member yet? Sign up for a Membership - just USD 49/year.
Already a Member? Log into your account to download the report.

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.